Biomea Fusion, Inc. (BMEA)
Nasdaq: BMEA · Pharmaceutical Preparations · San Carlos, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 24, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 28, 2023 | Feb 28, 2022 | · | · |
| For lenders | |||||||
| Net interest income | 1,858 | 5,644 | 8,880 | · | · | · | · |
| Research and development | 61,979 | 118,085 | 102,546 | 62,713 | 27,996 | 3,671 | 1,092 |
| General and administrative | 19,328 | 25,985 | 23,589 | 20,921 | 13,671 | 1,656 | 103 |
| Total operating expenses | 83,512 | 144,070 | 126,135 | 83,634 | 41,667 | 5,327 | 1,195 |
| Operating income | -83,512 | -144,070 | -126,135 | -83,634 | -41,667 | -5,327 | -1,195 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | · |
| Net income including non-controlling interests | -61,797 | -138,426 | -117,255 | -81,828 | -41,567 | -5,324 | -1,198 |
| Net income | -61,797 | -138,426 | -117,255 | -81,828 | -41,567 | -5,324 | -1,198 |
| Earnings per share, basic | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | · |
| Earnings per share, diluted | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.74 | -0.51 | -0.20 |
| Weighted average shares, basic | 52,228,068 | 36,105,671 | 34,106,923 | 29,271,777 | 23,858,552 | 10,532,942 | · |
| Weighted average shares, diluted | 52,228,068 | 36,105,671 | 34,106,923 | 29,271,777 | 23,858,552 | 10,532,942 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 23,858,552 | 10,532,942 | 6,051,712 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted